ArticleJournal of Taibah University Medical Sciences2024
Article in Journal of Taibah University Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Concerns over the increasing number of obese individuals and the associated health risks have prompted therapeutic option explorations. Similarly, this study aimed to establish Methods: The polyphenolic compounds in SCFE were identified with Reverse phase-high performance liquid chromatography (RP-HPLC). Meanwhile, murine 3T3-L1 preadipocytes, measuring leptin levels, reactive oxygen species (ROS), and lipid and triglyceride (TG) contents were utilized during anti-adipogenic activity assessments. Concurrently, the effects of SCFE on adipogenic transcription factors were established with quantitative real-time-polymerase chain reaction (qRT-PCR). Results: The RP-HPLC results indicated three polyphenolic compounds in SCFE, including one flavonoid (naringin) and two phenolic acids (syringic and p-coumaric). Although SCFE treatments (250-1000 μg/mL) did not result in cell toxicity, they significantly reduced dose-dependent lipid accumulation, ROS production, and TG and leptin levels relative to control-differentiated adipocytes. Moreover, SCFE suppressed sterol regulatory element binding protein-1 (SREBP-1), peroxisome proliferator-activated receptor-gamma (PPAR-γ), and CCAAT/enhancer-binding protein-alpha (C/EBP-α) gene expressions during preadipocyte differentiation into adipocytes. Conclusion: The findings revealed the anti-adipogenic properties of SCFE, indicating its potential as a natural obesity management remedy. Nevertheless, more studies are necessary to elucidate the reactions resulting in SCFE anti-adipogenic effects and the active constituents responsible for the property.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.